<bill session="115" type="h" number="5811" updated="2023-01-11T13:39:31Z">
  <state datetime="2018-06-19T15:16:10-04:00">PASS_OVER:HOUSE</state>
  <status>
    <unknown datetime="2018-06-19T15:16:10-04:00"/>
  </status>
  <introduced datetime="2018-05-15"/>
  <titles>
    <title type="display">Long-Term Opioid Efficacy Act of 2018</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act with respect to postapproval study requirements for certain controlled substances, and for other purposes.</title>
    <title type="short" as="introduced">Long-Term Opioid Efficacy Act of 2018</title>
  </titles>
  <sponsor bioguide_id="M001166"/>
  <cosponsors>
    <cosponsor bioguide_id="B001243" joined="2018-06-07"/>
    <cosponsor bioguide_id="G000568" joined="2018-05-15"/>
    <cosponsor bioguide_id="W000791" joined="2018-06-07"/>
  </cosponsors>
  <actions>
    <action datetime="2018-05-15">
      <text>Introduced in House</text>
    </action>
    <action datetime="2018-05-15" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2018-05-17">
      <text>Committee Consideration and Mark-up Session Held.</text>
    </action>
    <action datetime="2018-05-17" state="REPORTED">
      <text>Ordered to be Reported (Amended) by Voice Vote.</text>
    </action>
    <action datetime="2018-06-19T15:11:27-04:00">
      <text>Mr. Walden moved to suspend the rules and pass the bill, as amended.</text>
    </action>
    <action datetime="2018-06-19T15:12:00-04:00">
      <text>Considered under suspension of the rules.</text>
      <reference ref="CR H5243-5244" label="consideration"/>
    </action>
    <action datetime="2018-06-19T15:12:02-04:00">
      <text>DEBATE - The House proceeded with forty minutes of debate on H.R. 5811.</text>
    </action>
    <vote how="by voice vote" type="vote" datetime="2018-06-19T15:16:10-04:00" where="h" result="pass" state="PASS_OVER:HOUSE">
      <text>On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.</text>
      <reference ref="CR H5243" label="text"/>
    </vote>
    <action datetime="2018-06-19T15:16:11-04:00">
      <text>Motion to reconsider laid on the table Agreed to without objection.</text>
    </action>
    <action datetime="2018-06-20">
      <text>Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Markup, Referral"/>
  </committees>
  <relatedbills>
    <bill session="115" type="h" number="6" relation="unknown"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug trafficking and controlled substances"/>
    <term name="Licensing and registrations"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2019-08-20T18:32:02Z" status="Introduced in House">Long-Term Opioid Efficacy Act of 2018

This bill expands the authority of the Food and Drug Administration (FDA)to require post-approval studies or clinical trials with respect to controlled substances (e.g., opioids).</summary>
</bill>
